Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration.
Daily hassles reported by Dutch multiple sclerosis patients.
Efficient transdifferentiation of human adipose-derived stem cells into Schwann-like cells: A promise for treatment of demyelinating diseases.
Idiopathic inflammatory demyelinating diseases of the central nervous system in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors and survival.
A small molecule binding HMGB1 and HMGB2 inhibits microglia-mediated neuroinflammation.
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS
Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Fulminant Central Plus Peripheral Nervous System Demyelination without Antibodies to Neurofascin.
Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis.
A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
Are there Epstein-Barr virus seronegative patients with multiple sclerosis?
Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis.
First patient enrolled in third Phase III study of oral laquinimod for relapsing-remitting multiple sclerosis
Biologic therapies: lessons from multiple sclerosis.
Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient.
FTY720 is neuroprotective after cuprizone-induced central nervous system demyelination.
[Differential diagnosis of late-stage neuroborreliosis with affection of the central nervous system.]
Psychiatric symptoms in patients with multiple sclerosis.
Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis.
Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain.
1st International Symposium on Gait and Balance in MS: Gait and Balance Measures in the Evaluation of People with MS.
Sarcoidosis Triggered by Interferon-Beta Treatment of Multiple Sclerosis: A Case Report and Focused Literature Review.
MSQoL-54 predicts change in fatigue after inpatient rehabilitation for people with multiple sclerosis.
Natalizumab modulates the humoral response against HERV-Wenv73-88 in a follow-up study of Multiple Sclerosis patients.
Humoral mechanisms in T cell vaccination: induction and functional characterization of anti-lymphocytic autoantibodies.

Pages